Display options
Cite
Qin L, Qin W, Wang J, et al. Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate. Exp Ther Med. 2017;14(5):5012-5016doi: 10.3892/etm.2017.5115.
Qin, L., Qin, W., Wang, J., & Lin, L. (2017). Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate. Experimental and therapeutic medicine, 14(5), 5012-5016. https://doi.org/10.3892/etm.2017.5115
Qin, Lili, et al. "Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate." Experimental and therapeutic medicine vol. 14,5 (2017): 5012-5016. doi: https://doi.org/10.3892/etm.2017.5115
Qin L, Qin W, Wang J, Lin L. Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate. Exp Ther Med. 2017 Nov;14(5):5012-5016. doi: 10.3892/etm.2017.5115. Epub 2017 Sep 12. PMID: 29201206; PMCID: PMC5704275.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2017 Nov;14(5):5012-5016. doi: 10.3892/etm.2017.5115. Epub 2017 Sep 12.

Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate.

Experimental and therapeutic medicine

Lili Qin, Wenjun Qin, Jianfei Wang, Lin Lin

Affiliations

  1. Department of Nephrology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.
  2. Department of Urology, Hanting People's Hospital of Weifang, Weifang, Shandong 261100, P.R. China.
  3. Department of Radiology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.

PMID: 29201206 PMCID: PMC5704275 DOI: 10.3892/etm.2017.5115

Abstract

This study investigated the effects of alprostadil combined with calcium dobesilate on the treatment of diabetic nephropathy. We recruited 80 patients with diabetic nephropathy, who were randomly divided into experimental (n=40) and control (n=40) groups. Patients received high-quality low-protein diabetic diet intervention and subcutaneous injection of insulin to adjust blood glucose, combined with antihypertensive, antiplatelet drugs, and other comprehensive treatments. The control group received alprostadil and the experimental group received alprostadil combined with calcium dobesilate. Both groups were treated for 12 weeks as one treatment cycle. The time to remission of clinical symptoms such as mental fatigue and weakness, limb edema, soreness and swelling of waist and knee, cold limbs and limb numbness and pain was significantly shorter in the experimental group than that in the control group (p<0.05). After intervention, the blood levels of small molecular weight proteins, such as β2-microglobulin (β2-MG), cystatin C (CysC), and retinol binding protein (RBP), were significantly lower in the experimental group than those in the control group (p<0.05). The levels of the inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP) were significantly lower in the experimental group than those in the control group (p<0.05). The levels of 25-hydroxyvitamin D and parathyroid hormone were significantly higher in the experimental group than those in the control group (p<0.05). The level of angiotensin II was lower in the experimental group than that in the control group (p<0.05) and the level of fasting serum insulin was significantly higher in the experimental group than that in the control group (p<0.05). The homeostasis model assessment of insulin resistance (HOMA-IR) index was lower in the experimental group than that in the control group (p<0.05). The levels of renal function indexes, blood urea nitrogen, creatinine and uric acid, in experimental group were lower than those in control group (p<0.05). The levels of brain derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1) were significantly higher in both groups after the intervention than those before the intervention (p<0.05). The levels of BDNF and IGF-1 were higher in the experimental group than that in control group after intervention (p<0.05). The application of alprostadil combined with calcium dobesilate in patients with diabetic nephropathy can effectively relieve clinical symptoms, improve renal functions, reduce blood levels small proteins, alleviate the inflammatory response, and regulate the levels of BDNF and IGF-1, thus improving the clinical treatment effect.

Keywords: alprostadil; calcium dobesilate; diabetic nephropathy

References

  1. Arch Physiol Biochem. 2016 Oct;122(4):186-194 - PubMed
  2. Br J Nutr. 2016 Oct;116(8):1326-1335 - PubMed
  3. Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F291-F307 - PubMed
  4. J Ethnopharmacol. 2016 Aug 2;189:238-49 - PubMed
  5. Mol Med Rep. 2016 Jul;14 (1):920-6 - PubMed
  6. Diabetes Metab Syndr. 2016 Oct - Dec;10 (4):247-249 - PubMed
  7. Immunol Lett. 2017 Jun;186:52-58 - PubMed
  8. Antioxid Redox Signal. 2016 Nov 1;25(13):732-748 - PubMed
  9. Trends Endocrinol Metab. 2016 Nov;27(11):820-830 - PubMed
  10. Diabetes Metab J. 2016 Dec;40(6):473-481 - PubMed
  11. Diabetes Technol Ther. 2016 Jul;18(7):405-7 - PubMed
  12. J Assoc Physicians India. 2016 Jul;64(7):34-38 - PubMed
  13. Sci Rep. 2017 Apr 21;7(1):1236 - PubMed
  14. Horm Metab Res. 2016 Sep;48(9):620 - PubMed
  15. Sci Rep. 2016 May 25;6:26740 - PubMed
  16. Clin Proteomics. 2016 Oct 15;13:22 - PubMed
  17. Kidney Blood Press Res. 2016;41(3):311-24 - PubMed
  18. Biomed Pharmacother. 2016 Oct;83:92-99 - PubMed
  19. Mol Med Rep. 2016 Jul;14 (1):963-8 - PubMed
  20. Endocrine. 2016 Oct;54(1):81-92 - PubMed

Publication Types